Roche 9-month pharma sales strong, but demand for COVID-19 products down

19 October 2023

Swiss pharma giant Roche (ROG: SIX) saw its shares fall more than 5% to 254.60 francs this morning, after it posted a cautious forecast for full-year 2023.

The warning came along with the release of nine-month financials showing that group sales grew by 1% at constant exchange rates (CER) in the first nine months to 44,053 million francs ($15.9 billion), and seeing strong increase of 7% in the third quarter.

Pharmaceutical Division sales increased 9% to 33,622 million francs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK